Advertisement


Jame Abraham, MD, on HER2-Positive Breast Cancer: Results of the BCIRG-006 Study

2015 San Antonio Breast Cancer Symposium

Advertisement

Jame Abraham, MD, of the Cleveland Clinic, discusses the 10-year follow-up of this trial, and the long-term benefit and safety of adding trastuzumab to the adjuvant treatment of HER2-positive early breast cancer (Abstract S5-04).



Related Videos

Breast Cancer

Judy E. Garber, MD, MPH, on Clinical Applications of Hereditary Multigene Panels

Judy E. Garber, MD, MPH, of the Dana-Farber Cancer Institute, gives her expert perspective on this vital and timely topic.

Breast Cancer

Gunter von Minckwitz, MD: Early Survival Analysis of GeparSixto

Gunter von Minckwitz, MD, of the German Breast Group, discusses data from this phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (Abstract S2-05).

Breast Cancer
Symptom Management

Andrew Seidman, MD, and Hope Rugo, MD, on Reducing Alopecia: FDA Approves New Device

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss the recent approval of a cooling cap to reduce hair loss during chemotherapy.

Breast Cancer
Cost of Care

Benjamin D. Smith, MD, on Mastectomy vs Lumpectomy: Complications and Costs

Benjamin D. Smith, MD, of the MD Anderson Cancer Center, discusses the higher complication rates and economic burdens of mastectomy plus reconstruction vs lumpectomy plus radiation in early breast cancer (Abstract S3-07).

Breast Cancer

Clifford Hudis, MD, and William Gradishar, MD: Expert Perspective

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and William J. Gradishar, MD, of the Lurie Comprehensive Cancer Center, discuss the most important papers and results at this year's San Antonio Breast Cancer Symposium.

Advertisement

Advertisement




Advertisement